Bubs is going to have a problem when the shortfall ends soon. It will not under our or other trade treaties be able to get any permanent opportunity over others. It has to somehow find that growth in our region to match the supply and that is unlikely. A2 had to consider all sorts of supply issues with this. That would have taken time .
Ann: Deferral of FDA consideration of enforcement discretion, page-131
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.32 |
Change
-0.160(2.92%) |
Mkt cap ! $3.851B | |||
| Open | High | Low | Value | Volume |
| $5.46 | $5.50 | $5.32 | $12.91M | 2.394M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 34432 | $5.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.37 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| A2M (ASX) Chart |